Targets › PPP3CA
2 programs from 2 companies in 4 trials: 3 Phase 4, 1 Phase 3; Immunology; next expected readout Jun 2027.
Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular Ca(2+)-mediated signals. Many of the substrates contain a PxIxIT motif and/or a LxVP motif. (UniProt, Q08209)
Open in Phaseline: the race on PPP3CA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals | voclosporin Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor | PPP3CA | Phase 4 | Lupus Nephritis | Mar 2029 |
| Qilu Pharmaceutical | Voclosporin (QL1074) Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor | PPP3CA | Phase 3 | Lupus Nephritis | Jun 2027 |
Lupus Nephritis (4)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.